Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Dabrafenib plus trametinib in patients with BRAF^V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.

Wen, Patrick Y; Stein, Alexander; van den Bent, Martin; De Greve, Jacques; Wick, Antje; de Vos, Filip Y F L; von Bubnoff, Nikolas; van Linde, Myra E; Lai, Albert; Prager, Gerald W; Campone, Mario; Fasolo, Angelica; Lopez-Martin, Jose A; Kim, Tae Min; Mason, Warren P; Hofheinz, Ralf-Dieter; Blay, Jean-Yves; Cho, Daniel C; Gazzah, Anas; Pouessel, Damien; Yachnin, Jeffrey; Boran, Aislyn; Burgess, Paul; Ilankumaran, Palanichamy; Gasal, Eduard; Subbiah, Vivek.

Lancet Oncol ; 23(1): 53-64, 2022 01.

Artigo em Inglês | MEDLINE | ID: mdl-34838156

2.

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.

Emamekhoo, Hamid; Olsen, Mark R; Carthon, Bradley C; Drakaki, Alexandra; Percent, Ivor J; Molina, Ana M; Cho, Daniel C; Bendell, Johanna C; Gordan, Lucio N; Rezazadeh Kalebasty, Arash; George, Daniel J; Hutson, Thomas E; Arrowsmith, Edward R; Zhang, Joshua; Zoco, Jesus; Johansen, Jennifer L; Leung, David K; Tykodi, Scott S.

Cancer ; 128(5): 966-974, 2022 03 01.

Artigo em Inglês | MEDLINE | ID: mdl-34784056

3.

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.

Shapiro, Geoffrey I; LoRusso, Patricia; Cho, Daniel C; Musib, Luna; Yan, Yibing; Wongchenko, Matthew; Chang, Ilsung; Patel, Premal; Chan, Iris T; Sanabria-Bohorquez, Sandra; Meng, Raymond D; Bendell, Johanna C.

Invest New Drugs ; 39(1): 163-174, 2021 02.

Artigo em Inglês | MEDLINE | ID: mdl-32737717

4.

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Olencki, Thomas E; Tarazi, Jamal C; Rosbrook, Brad; Fernandez, Kathrine C; Lechuga, Mariajose; Choueiri, Toni K.

Lancet Oncol ; 19(3): 405-415, 2018 03.

Artigo em Inglês | MEDLINE | ID: mdl-29439857

5.

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Ghamande, Sharad; Lin, Chia-Chi; Cho, Daniel C; Shapiro, Geoffrey I; Kwak, Eunice L; Silverman, Michael H; Tseng, Yunlong; Kuo, Min-Wen; Mach, Wendy B; Hsu, Shu-Chi; Coleman, Teresa; Yang, James Chih-Hsin; Cheng, Ann-Lii; Ghalib, Mohammad H; Chuadhary, Imran; Goel, Sanjay.

Invest New Drugs ; 32(3): 445-51, 2014 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-24271274

6.

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.

Zhu, Shudong; Cohen, Matthew B; Bjorge, Jeffrey D; Mier, James W; Cho, Daniel C.

J Cell Mol Med ; 17(3): 377-85, 2013 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-23387989

7.

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Munster, Pamela; Iannotti, Nicholas; Cho, Daniel C; Kirkwood, John M; Villaruz, Liza C; Gibney, Geoffrey T; Hodi, F Stephen; Mettu, Niharika B; Jones, Mark; Bowman, Jill; Smith, Michael; Lakshminarayanan, Mani; O'Day, Steven.

Cancer Res Commun ; 3(12): 2572-2584, 2023 12 19.

Artigo em Inglês | MEDLINE | ID: mdl-38115208

8.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y; Dietrich, Sascha; de Jonge, Maja J A; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C; de Vos, Filip Y F L; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H M; Zielinski, Christoph C; Redhu, Suman; Boran, Aislyn; Passos, Vanessa Q; Ilankumaran, Palanichamy; Bang, Yung-Jue.

Nat Med ; 29(5): 1103-1112, 2023 05.

Artigo em Inglês | MEDLINE | ID: mdl-37059834

9.

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).

Postel-Vinay, Sophie; Lam, Vincent K; Ros, Willeke; Bauer, Todd M; Hansen, Aaron R; Cho, Daniel C; Stephen Hodi, F; Schellens, Jan H M; Litton, Jennifer K; Aspeslagh, Sandrine; Autio, Karen A; Opdam, Frans L; McKean, Meredith; Somaiah, Neeta; Champiat, Stephane; Altan, Mehmet; Spreafico, Anna; Rahma, Osama; Paul, Elaine M; Ahlers, Christoph M; Zhou, Helen; Struemper, Herbert; Gorman, Shelby A; Watmuff, Maura; Yablonski, Kaitlin M; Yanamandra, Niranjan; Chisamore, Michael J; Schmidt, Emmett V; Hoos, Axel; Marabelle, Aurelien; Weber, Jeffrey S; Heymach, John V.

J Immunother Cancer ; 11(3)2023 03.

Artigo em Inglês | MEDLINE | ID: mdl-36927527

10.

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cho, Daniel C; Hutson, Thomas E; Samlowski, Wolfram; Sportelli, Peter; Somer, Brad; Richards, Paul; Sosman, Jeffrey A; Puzanov, Igor; Michaelson, M Dror; Flaherty, Keith T; Figlin, Robert A; Vogelzang, Nicholas J.

Cancer ; 118(24): 6055-62, 2012 Dec 15.

Artigo em Inglês | MEDLINE | ID: mdl-22674198

11.

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.

Tannir, Nizar M; Cho, Daniel C; Diab, Adi; Sznol, Mario; Bilen, Mehmet A; Balar, Arjun V; Grignani, Giovanni; Puente, Erika; Tang, Lily; Chien, David; Hoch, Ute; Choudhury, Arkopal; Yu, Danni; Currie, Sue L; Tagliaferri, Mary A; Zalevsky, Jonathan; Siefker-Radtke, Arlene O; Hurwitz, Michael E.

J Immunother Cancer ; 10(4)2022 04.

Artigo em Inglês | MEDLINE | ID: mdl-35444058

12.

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.

Siefker-Radtke, Arlene O; Cho, Daniel C; Diab, Adi; Sznol, Mario; Bilen, Mehmet A; Balar, Arjun V; Grignani, Giovanni; Puente, Erika; Tang, Lily; Chien, David; Hoch, Ute; Choudhury, Arkopal; Yu, Danni; Currie, Sue L; Tagliaferri, Mary A; Zalevsky, Jonathan; Hurwitz, Michael E; Tannir, Nizar M.

Eur Urol ; 82(4): 365-373, 2022 10.

Artigo em Inglês | MEDLINE | ID: mdl-35643589

13.

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis, Elizabeth J; Martin-Liberal, Juan; Kristeleit, Rebecca; Cho, Daniel C; Blagden, Sarah P; Berthold, Dominik; Cardin, Dana B; Vieito, Maria; Miller, Rowan E; Hari Dass, Prashanth; Orcurto, Angela; Spencer, Kristen; Janik, John E; Clark, Jason; Condamine, Thomas; Pulini, Jennifer; Chen, Xuejun; Mehnert, Janice M.

J Immunother Cancer ; 10(10)2022 10.

Artigo em Inglês | MEDLINE | ID: mdl-36316061

14.

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.

Sanborn, Rachel E; Pishvaian, Michael J; Callahan, Margaret K; Weise, Amy; Sikic, Branimir I; Rahma, Osama; Cho, Daniel C; Rizvi, Naiyer A; Sznol, Mario; Lutzky, Jose; Bauman, Julie E; Bitting, Rhonda L; Starodub, Alexander; Jimeno, Antonio; Reardon, David A; Kaley, Thomas; Iwamoto, Fabio; Baehring, Joachim M; Subramaniam, Deepa S; Aragon-Ching, Jeanny B; Hawthorne, Thomas R; Rawls, Tracey; Yellin, Michael; Keler, Tibor.

J Immunother Cancer ; 10(8)2022 08.

Artigo em Inglês | MEDLINE | ID: mdl-35940825

15.

Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.

Pandya, Shuchi S; Mier, James W; McDermott, David F; Cho, Daniel C.

BJU Int ; 108(8 Pt 2): E245-9, 2011 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-21320274

16.

mTOR inhibitors in renal cell carcinoma.

Battelli, Chiara; Cho, Daniel C.

Therapy ; 8(4): 359-367, 2011 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-21894244

17.

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.

Sanborn, Rachel E; Hamid, Omid; de Vries, Elisabeth Ge; Ott, Patrick A; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A; Cho, Daniel C; Plummer, Ruth; Stroh, Mark; Lu, Lawrence; Thistlethwaite, Fiona.

J Immunother Cancer ; 9(7)2021 07.

Artigo em Inglês | MEDLINE | ID: mdl-34301808

18.

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.

Atkins, Michael B; Plimack, Elizabeth R; Puzanov, Igor; Fishman, Mayer N; McDermott, David F; Cho, Daniel C; Vaishampayan, Ulka; George, Saby; Tarazi, Jamal C; Duggan, William; Perini, Rodolfo; Thakur, Mahgull; Fernandez, Kathrine C; Choueiri, Toni K.

Eur J Cancer ; 145: 1-10, 2021 03.

Artigo em Inglês | MEDLINE | ID: mdl-33412465

19.

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.

Diab, Adi; Tykodi, Scott S; Daniels, Gregory A; Maio, Michele; Curti, Brendan D; Lewis, Karl D; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander I; Cho, Daniel C; Guan, Shanhong; Puente, Erika; Nguyen, Tuan; Hoch, Ute; Currie, Sue L; Lin, Wei; Tagliaferri, Mary A; Zalevsky, Jonathan; Sznol, Mario; Hurwitz, Michael E.

J Clin Oncol ; 39(26): 2914-2925, 2021 09 10.

Artigo em Inglês | MEDLINE | ID: mdl-34255535

20.

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.

McDermott, David F; Lee, Jae-Lyun; Bjarnason, Georg A; Larkin, James M G; Gafanov, Rustem A; Kochenderfer, Mark D; Jensen, Niels Viggo; Donskov, Frede; Malik, Jahangeer; Poprach, Alexandr; Tykodi, Scott S; Alonso-Gordoa, Teresa; Cho, Daniel C; Geertsen, Poul F; Climent Duran, Miguel Angel; DiSimone, Christopher; Silverman, Rachel Kloss; Perini, Rodolfo F; Schloss, Charles; Atkins, Michael B.

J Clin Oncol ; 39(9): 1020-1028, 2021 03 20.

Artigo em Inglês | MEDLINE | ID: mdl-33529051

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar: